However, elafin also promotes cell proliferation through its activation of the MAP kinase pathway and has also been associated with chemoresistance via Bcl-Xl expression in high-grade serous ovarian cancers and basal-like breast tumors [13]. Here, BCL2L1 is linked to breast neoplasm.